Kinase inhibitors for advanced medullary thyroid carcinoma

Authors

  • Martin Schlumberger University Paris-Sud XI; Institut Gustave Roussy; Department of Nuclear Medicine and Endocrine Oncology; Centre de Référence Tumeurs Réfractaires de la Thyroïde
  • Marie-Hélène Massicotte University Paris-Sud XI; Institut Gustave Roussy; Department of Nuclear Medicine and Endocrine Oncology; Centre de Référence Tumeurs Réfractaires de la Thyroïde
  • Camila L. Nascimento University Paris-Sud XI; Institut Gustave Roussy; Department of Nuclear Medicine and Endocrine Oncology; Centre de Référence Tumeurs Réfractaires de la Thyroïde
  • Cécile Chougnet University Paris-Sud XI; Institut Gustave Roussy; Department of Nuclear Medicine and Endocrine Oncology; Centre de Référence Tumeurs Réfractaires de la Thyroïde
  • Eric Baudin University Paris-Sud XI; Institut Gustave Roussy; Department of Nuclear Medicine and Endocrine Oncology; Centre de Référence Tumeurs Réfractaires de la Thyroïde
  • Sophie Leboulleux University Paris-Sud XI; Institut Gustave Roussy; Department of Nuclear Medicine and Endocrine Oncology; Centre de Référence Tumeurs Réfractaires de la Thyroïde

DOI:

https://doi.org/10.6061/clinics/2012(Sup01)21

Keywords:

Thyroid Neoplasms, Molecular Targeted Therapy

Abstract

The recent availability of molecular targeted therapies leads to a reconsideration of the treatment strategy for patients with distant metastases from medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered.

Downloads

Download data is not yet available.

Downloads

Published

2012-01-01

Issue

Vol. 67 No. supl.1 (2012)

Section

Reviews

How to Cite

Kinase inhibitors for advanced medullary thyroid carcinoma. (2012). Clinics, 67(supl.1), 125-129. https://doi.org/10.6061/clinics/2012(Sup01)21